COVID-19: Prevent New Infections

Scripps Research is leveraging its expertise in structural biology and immunology to understand how the new coronavirus interacts with our immune system at the molecular level, identify and design antibodies that could serve as the basis for a vaccine, and develop diagnostic tools and novel vaccine approaches.

Super-potent human antibodies protect against COVID-19 in animal tests
A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against the coronavirus that causes the disease. Read more

 

Antibodies produced in response to one type of coronavirus don’t offer protection against the other, study suggests
Even though the coronaviruses that cause SARS and COVID-19 are closely related and infect cells the same way, they aren’t cross-protective in cell culture experiments. Read more

 

Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research
Clinical trials are assessing whether the drug can temper the immune system’s response to coronavirus in the lungs, preventing the dangerous inflammation seen in patients with severe disease. Read more

 

Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the coronavirus at the root of COVID-19. Read more

 

COVID-19 survivors needed for Scripps Research antibody study
Antibodies that are circulating in the blood of patients who’ve recovered from COVID-19 may serve as the key to developing an effective vaccine against the virus. Survivors can donate blood at San Diego locations.  Read more

JOIN ▸

Antibodies, Vaccines and the Current State of COVID-19
An extended conversation between Dr. Eric Topol, Director of the Scripps Research Translational Institute, and Professor Dennis Burton, Chair of the Department of Immunology and Microbiology at Scripps Research. Listen as they talk about antibody cocktail treatments, the mystery of “longhaul” COVID-19 symptoms and how close we are to developing a coronavirus vaccine.

PreSCRIPPSion Sound podcast version of the conversation
Read full transcript

 

Front Row Lecture Series: Designing Universal Vaccines for Influenza and Coronaviruses
As the ongoing COVID-19 pandemic edges up on the onset of flu season, the need for effective vaccines for these viruses and others is abundantly clear. In this Front Row Lecture, Ian Wilson, DPhil, chair of Scripps Research's Department of Integrative Structural and Computational Biology, discusses advances in designing and developing universal vaccines that could either treat or protect people against all strains of a virus. He focuses on progress developing universal vaccines against influenza and how research on flu has paved the way for current efforts to find a pan-coronavirus vaccine.

 

Front

Front Row Lecture Series: Survivors of Coronavirus Infections May Hold the Secret to Stopping COVID-19
Soon after the COVID-19 pandemic reached the United States, a team of Scripps Research scientists began studying blood samples from patients recovering from infection by the novel coronavirus. In this virtual Front Row lecture, Dennis Burton, PhD, shared how he and his collaborators are analyzing COVID-19 survivors' blood for proteins, known as antibodies, that the immune system creates after encountering the virus. Antibodies to the new coronavirus could be used as much-needed therapeutics to COVID-19 or to help design a vaccine to protect against the disease.

 

Front Row Lecture Series: Addressing the Coronavirus Challenge
How do scientists create vaccines and drugs against a virus that simply didn’t exist months ago? That’s the challenge that virologist Michael Farzan, PhD, is facing head on—along with his team on the Jupiter, Florida, campus of Scripps Research. In this Front Row lecture, Farzan, a professor and co-chair of the Department of Immunology and Microbiology, shares his early findings on efforts to develop a safe and effective vaccine that triggers antibodies against the novel coronavirus.

 

Front Row Lecture Series: Outsmarting Emerging Pathogens in an Interconnected World
Kristian Andersen, PhD, a genomic epidemiologist, was among the first to begin tracing the origins and spread of the novel coronavirus based on public genome sequencing data. In this virtual Front Row lecture, Andersen shares unique insights on how COVID-19 emerged and he explains what has worked (and hasn’t worked) to mitigate the public health crisis. Lessons learned can help us contain the current pandemic and prepare for future outbreaks.

 

Coronavirus structure may hold key to treatment: Scripps Research COVID-19 updates
Andrew Ward, PhD, a professor of Integrative Structural and Computational Biology, revealed the first structure of a human coronavirus spike protein in 2017 from the HKU1 virus, and went on to do the same for SARS and MERS. He and his team are now investigating the structure of the SARS-CoV-2 spike protein and working with collaborators to isolate antibodies from patients. They also developed new imaging methods that may work as a diagnostic tool to probe blood samples from those with COVID-19. 

 

Antibodies, biologics and the fight against coronavirus: Scripps Research COVID-19 updates
Besides vaccines and antiviral drugs, a group of medicines called biologics offer great potential in the battle against COVID-19. Serum from recovered patients can be used to protect others and also to identify useful antibodies, our immune system’s precision germ-targeting system. In Jupiter, Florida, Scripps Research molecular biologist Christoph Rader, PhD, explains.

 

Using the immune response to develop coronavirus treatments and vaccines: Scripps Research COVID-19 updates
Dennis Burton, PhD, and Thomas Rogers, MD, PhD, are studying the human immune response to SARS-CoV-2 infections and working to identify antibodies that may serve as the basis for vaccines or antiviral therapies. They need volunteers who have recovered from COVID-19 to help with their research. If you are interested in helping, contact Karen Westfall at kwestfall@scripps.edu.

 

How does the coronavirus sicken people? A virologist explains: Scripps Research COVID-19 updates
The pandemic strain of coronavirus infects cells in the lung, leading to an aggressive immune response that can be life-threatening. Virologist Hyeryun Choe, PhD, at Scripps Research, Florida answers common questions about COVID-19.

 

How scientists are confronting coronavirus: Scripps Research COVID-19 updates
Around the world, scientists are sharing data, sharing insights, pushing for the best possible vaccines and medications against COVID-19. Virologist Michael Farzan, PhD, describes the scale of the effort underway at Scripps Research.